Last updated: February 15, 2026
Overview of the Drug
NDC 43598-0429 is identified as a biosimilar, specifically the biosimilar version of Remicade (infliximab). Approved by the FDA in 2015, this drug is used for autoimmune conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. Biosimilars like this aim to provide cost-effective alternatives to originator biologics upon patent expiration.
Current Market Landscape
The infliximab market has undergone significant growth driven by patent expiries of the original drug and increasing adoption of biosimilars. Key players include Johnson & Johnson (Remicade, originator), and several biosimilar manufacturers such as Pfizer, Celltrion, and Boehringer Ingelheim.
- Market Size: The global infliximab market was valued at approximately $7 billion in 2021, with biosimilars accounting for around 25% of that volume, equivalent to roughly $1.75 billion.
- Market Share Distribution: The biosimilar share is concentrated in North America and Europe, with regulators approving multiple biosimilar versions since 2016.
- Pricing Dynamics: Biosimilar introductions have reduced prices of infliximab by 20-40% relative to the originator, with geographic variations.
Pricing Data and Trends
- Average Wholesale Price (AWP): The originator drug’s AWP exceeds $900 per 100 mg vial.
- Biosimilar Price Range: Current biosimilar AWP ranges from $600 to $700 per 100 mg vial in the U.S.
- Market Penetration: Biosimilars constitute approximately 20-30% of infliximab prescriptions in the U.S. as of 2022, with a trend toward increased uptake as rebates and formulary policies favor biosimilar use.
Regulatory and Reimbursement Environment
The FDA approved multiple biosimilars for infliximab starting in 2016. The Centers for Medicare & Medicaid Services (CMS) classifies biosimilars at the same reimbursement rate as the originator under some circumstances, incentivizing their use.
Incentives and policies vary across countries but generally favor biosimilar adoption due to cost containment.
Price Projection Assumptions
- Market Growth Rate: 4% annually over the next five years, driven by broader biosimilar acceptance, increased indications, and expanded insurance coverage.
- Price Erosion Trend: Continued price reductions of 8-12% annually as biosimilar competition intensifies and supply chains stabilize.
- Market Penetration: Biosimilar share increases to 45-50% within five years, driven by policy shifts and prescriber acceptance.
Price Projection (Next 5 Years)
| Year |
Estimated Average Price (per 100 mg vial in USD) |
Key Drivers |
| 2023 |
$650 |
Current market, moderate savings |
| 2024 |
$600 |
Competitive pressure, increased biosimilar uptake |
| 2025 |
$550 |
Greater biosimilar market penetration |
| 2026 |
$510 |
Increased manufacturer competition |
| 2027 |
$470 |
Market saturation, further price reductions |
By 2027, biosimilar pricing is projected to stabilize around $470–$510 per 100 mg vial, representing significant savings relative to originator prices.
Implications for Stakeholders
- Manufacturers: Biosimilar entrants should focus on cost efficiencies to sustain margins amid price erosion.
- Payers: Cost savings from biosimilars drive formulary shifts; participating in strategic negotiations is critical.
- Providers: Greater biosimilar availability promotes competitive prescribing but requires education to ensure acceptance.
Summary
NDC 43598-0429, as a biosimilar for infliximab, occupies a growing segment in a multi-billion-dollar market. Prices are expected to decline approximately 8-12% annually over the next five years, stabilizing around $470–$510 per 100 mg vial by 2027.
Key Takeaways
- The infliximab biosimilar market expanded rapidly post-2016, with biosimilar prices 20-40% lower than originator drugs.
- Current biosimilar prices in the U.S. range from $600 to $700 per 100 mg vial.
- Projected price decline is approximately 8-12% annually through 2027, reaching around $470–$510.
- Market penetration of biosimilars is anticipated to increase to nearly 50%, driving further price compression.
- Policy incentives and increasing prescriber confidence will further influence pricing dynamics.
FAQs
1. What are the main competitors to NDC 43598-0429?
Other infliximab biosimilars approved by the FDA include Pfizer’s Inflectra (NDC 59236-0317), Celltrion’s Herzuma, and Boehringer Ingelheim’s Abbie. These are adjusting pricing and market strategies to capture share.
2. How does biosimilar pricing in the U.S. compare globally?
In Europe, biosimilar prices are generally 20-30% lower than originators, with some countries achieving even higher discounts through centralized procurement. U.S. prices are comparatively higher but have been decreasing steadily.
3. What factors influence biosimilar adoption?
Regulatory approval, reimbursement policies, prescriber awareness, and manufacturer pricing strategies significantly impact biosimilar market share.
4. Can biosimilar prices decline further after 2027?
Yes, continued competition, patent challenges, and evolving market policies could further compress prices beyond the projected period.
5. How will price changes affect manufacturer revenue?
Price erosion may reduce revenue per unit but can be offset by increased volume as biosimilars gain market share and acceptance expands.
Sources
- EvaluatePharma. "Global Biosimilars Market Size & Forecast."
- IQVIA. "U.S. Biosimilar Market Data, 2022."
- FDA. "Biosimilar Approval Details, 2015–2022."
- CMS. "Medicare Part B Reimbursement Policies for Biosimilars."
- MarketWatch. "Infliximab Biosimilar Price Trends."
